1. Home
  2. FLUX vs MRKR Comparison

FLUX vs MRKR Comparison

Compare FLUX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flux Power Holdings Inc.

FLUX

Flux Power Holdings Inc.

HOLD

Current Price

$1.05

Market Cap

23.3M

Sector

Miscellaneous

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.57

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLUX
MRKR
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
24.2M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
FLUX
MRKR
Price
$1.05
$1.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
132.2K
58.1K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
33.61
EPS
N/A
N/A
Revenue
$9,317,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.01
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
126.25
N/A
52 Week Low
$0.91
$0.81
52 Week High
$7.55
$4.07

Technical Indicators

Market Signals
Indicator
FLUX
MRKR
Relative Strength Index (RSI) 48.18 61.72
Support Level $1.04 $1.35
Resistance Level $1.20 $1.69
Average True Range (ATR) 0.07 0.06
MACD 0.01 0.01
Stochastic Oscillator 72.39 90.91

Price Performance

Historical Comparison
FLUX
MRKR

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: